Analog Devices Issues Q1 Outlook - Quick Facts

Analog Devices, Inc. (ADI) said, for the first quarter of fiscal 2023, the company is forecasting revenue of $3.15 billion, +/- $100 million. The company is planning for
reported EPS to be $1.71, +/- $0.10, and adjusted EPS to be $2.60, +/- $0.10. Analysts polled by Thomson Reuters expect the company to report profit per share of $2.41 on revenue of $3.04 billion. Analysts' estimates typically exclude special items.

Fourth quarter earnings were at $936.23 million, or $1.82 per share compared with $75.69 million, or $0.16 per share, prior year. Excluding items, adjusted earnings were $2.73 per share for the period. Analysts on average had expected the company to earn $2.58 per share, according to figures compiled by Thomson Reuters. Revenue for the quarter rose 38.9% to $3.25 billion from $2.34 billion last year.

The ADI Board has declared a quarterly cash dividend of $0.76 per outstanding share of common stock. The dividend will be paid on December 15, 2022 to all shareholders of record at the close of business on December 5, 2022.

Shares of Analog Devices are up 3% in pre-market trade on Tuesday.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Elon Musk's brain implant firm Neuralink said it has received approval from the U.S. Food and Drug Administration to conduct first-in-human clinical trials. In a tweet, Neuralink said, "We are excited to share that we have received the FDA's approval to launch our first-in-human clinical study! T.W. Garner Food Co. is recalling 50,688 bottles of 12 oz. Texas Pete Buffalo Wing Sauce citing undeclared soy, the U.S. Food and Drug Administration said. The agency noted that some of the bottles may contain Texas Pete Extra Mild Wing Sauce which contains soy. The recall involves Texas Pete Buffalo Wing Sauce with best used by 120623T 065239 UPC 0 75500 10011 6. The U.S. Food and Drug Administration approved Pfizer Inc's COVID-19 oral antiviral pill Paxlovid for the treatment of mild-to-moderate COVID-19 in adults. Paxlovid is the first oral treatment, and the fourth drug, approved by the agency to treat COVID-19 in adults. Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) has been approved to treat adults who are at high...
Follow RTT